Kalytera Therapeutics (OTCMKTS:KALTF) Moves Closer To A Fully Vertically Integrated Company Status

Kalytera Therapeutics (OTCMKTS:KALTF) Moves Closer To A Fully Vertically Integrated Company Status

This year has seen Kalytera
Therapeutics (OTCMKTS:KALTF)
engaged in numerous deals aimed at expanding
the company’s scope. The company has set clear objectives concerning what it
expects to achieve this year. One of these objectives is to be a fully
vertically integrated company.

Acquisition of a CBD
extraction firm

In late June 2019, Kalytera signed
a letter of intent (LOI) to buy into Oregon 01. This is a cannabidiol (CBD)
extraction company based in Oregon. Operating under Clean Bi Design as its
business name, the firm has the capability to produce around 600 kg of CBD
isolate for a single shift every month.

The Clean Bi Design facility is duly certified by the FDA
and GMP and has extraction equipment which is sure to optimize the extraction
activity. Notably, the equipment can perform extraction, isolation and
distillation all at the same time. Kalytera expects to begin operation at the
facility by the fourth quarter 2019.

Clean Bi Design will cost Kalytera $3.5 million which will
give the company a 51% shareholding. According to the LOI, the deal should be
closed by early October.

A step closer to a
leadership position

The cannabis industry is just taking off, especially in the
US. But companies have to deal with complicated legal procedures just to hit
the ground running. This is due to the absence of a clear legal environment
regarding cannabis in the US.

Despite the complexities, Kalytera is determined to take
pole position in the industry. As per the company’s CEO and President, Robert
Farrell, the new acquisition should help Kalytera to cement its dominance of
the interface between consumer and medical CBD markets.

Kalytera intends to be a vertically integrated company and
Clean Bi Design is the right move toward that goal.

For starters, the company has interests in both medical and consumer markets in the cannabis industry. Just last month, KALTF revealed positive progress in the development of a CBD molecule which expedites pain relief.

As per the company, this molecule, dubbed KAL-1816, can ably
shut down the transmission of pain in conditions such as colitis, sciatica and
arthritis.

Published at Wed, 03 Jul 2019 12:01:18 +0000

Be the first to comment

Leave a Reply

Your email address will not be published.


*